TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...
"PICASSO will revolutionize photonic circuit architectures, from compute to light detection and ranging, by expanding the field’s focus from individual components to include a more holistic circuit- ...
MongoDB said additional partners and offerings are expected to be added to the startup program over time.
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Texas A&M AgriLife faculty, staff and graduate students earn Vice Chancellor’s Awards in Excellence honors at Texas A&M ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Introducing multiple Arm64 variants of the JIT_WriteBarrier function. Each variant is tuned for a GC mode. Because many parts ...
Social media has long been a valuable source of personally identifiable information (PII) for cybercriminals, but the rise of ...
Implementing predictive analytics can become one of the biggest competitive differentiators for any educational institution ...
New Space is a term now commonly used around the rocketry and satellite industries to indicate a new, speed focused model of ...
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback